$6.78
+0.13 (+1.95%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where NXTC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 5 with posted results
Held by 3 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, MILLENNIUM MANAGEMENT LLC, JANE STREET GROUP, LLC) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase I Study of SIM0505 in Participants With Advanced Solid TumorsNCT06792552dose escalation: Dose-limiting toxicity (DLT)Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: SIM0505 for injection, SIM0505 for injection | Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC), Papillary Renal Cell Carcinoma (Prcc), Uterine Serous Carcinoma (USC), NSCLC (Non-small Cell Lung Cancer), Primary Peritoneal Cancer | 738 | Feb 2028 | ≤ 558 d | 2026-08-17 |
| A Phase 1 Study of LNCB74 in Advanced Solid TumorsNCT06774963Evaluate the safety and tolerability of LNCB74Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: LNCB74 | Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer, Non-Small Cell Lung Cancer, Advanced or Metastatic Solid Tumors | 145 | Dec 2026 | ≤ 133 d | 2025-12-16 |
| A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsNCT05572684results2026-08-13Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. | Drug: NC410, pembrolizumab | Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer | 97 | 2025-04-30actual | — | 2026-08-13 |
| A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid NeoplasmsNCT05787496results2026-01-28To Evaluate the Frequency, Duration, and Severity of Treatment-emergent Adverse Events [Safety and Tolerability].Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: As a result of program reprioritization and due to the limited clinical activity observed in the Phase 1 trial, the study has been discontinued. | Drug: NC525 | Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome | 28 | 2025-01-31actual | — | 2026-01-28 |
| A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid TumorsNCT04875806results2025-04-22Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Due to the limited activity in Phase 1, NextCure decided to discontinue development of the anti-B7-H4 antibody monotherapy trial (NC762-01) to move forward with a prioritized B7-H4 ADC program. | Drug: NC762 | Advanced or Metastatic Solid Tumors, Ovarian Cancer, Non-small Cell Lung Cancer, Breast Cancer | 40 | 2024-01-30actual | — | 2025-04-22 |
| A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid TumorsNCT04408599results2024-07-25Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Upon completion of the Phase 1 portion of the NC410 monotherapy trial, NextCure focused efforts on a combination trial of NC410 in solid tumors. | Drug: NC410 | Advanced or Metastatic Solid Tumors, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer | 46 | 2023-07-06actual | — | 2024-07-25 |
| A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid TumorsNCT03665285results2024-03-08Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: NC318 | Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Melanoma, CRC, Urothelial Carcinoma, Cholangiocarcinoma | 109 | 2023-04-11actual | — | 2024-03-08 |
| A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLCNCT04430933Number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0Non-randomized · Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Upon reviewing current available combo studies, the sponsor decided to prioritize different combo study. | Drug: NC318, Pemetrexed/Carboplatin, Nab paclitaxel/Carboplatin, Docetaxel | Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer | 0 | 2022-06-30 | — | 2021-08-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19